Cosmos Health Inc (COSM)

$0.47 +0.01 (1.74%)
Market Cap 17.98M
Revenue (ttm) 54.43M
Net Income (ttm) -16.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -29.73%
Debt to Equity Ratio 0.41
Volume 659,000
Avg Vol 893,744
Day's Range N/A - N/A
Shares Out 37.43M
Stochastic %K 25%
Beta 5.37
Analysts Strong Buy
Price Target $4.50

Company Profile

Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, Croatia, Bulgaria, the United Arab Emirates, the United Kingdom, and Cyprus. The company offers prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It also provides ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvas...

Industry: Medical Distribution
Sector: Healthcare
Phone: 312 536 3102
Address:
141 West Jackson Boulevard, Suite 4236, Chicago, United States
Luvmepup
Luvmepup Feb. 4 at 5:56 AM
$COSM Remember this know-nothing? @marel_corp ... They thought they knew more than me and said this stock and CEO was so great! I guess they found out the hard way by not listening to me lol
0 · Reply
BettyGrigg
BettyGrigg Feb. 4 at 5:42 AM
$COSM Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research. https://www.globenewswire.com/news-release/2026/01/14/3218971/0/en/Cosmos-Health-Announces-Initiation-of-Analyst-Coverage-with-4-50-Valuation-by-Zacks-Small-Cap-Research.html $AMD
0 · Reply
LoisMaresi
LoisMaresi Feb. 4 at 5:04 AM
$COSM Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research. https://www.globenewswire.com/news-release/2026/01/14/3218971/0/en/Cosmos-Health-Announces-Initiation-of-Analyst-Coverage-with-4-50-Valuation-by-Zacks-Small-Cap-Research.html $SMCI
1 · Reply
LoisMaresi
LoisMaresi Feb. 4 at 5:02 AM
$COSM Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research. https://www.globenewswire.com/news-release/2026/01/14/3218971/0/en/Cosmos-Health-Announces-Initiation-of-Analyst-Coverage-with-4-50-Valuation-by-Zacks-Small-Cap-Research.html
0 · Reply
SlaveKing
SlaveKing Feb. 4 at 4:59 AM
$COSM So the CEO has been busy buying the stock... Interesting.
0 · Reply
BrandiBenes
BrandiBenes Feb. 4 at 4:57 AM
$COSM Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research. https://www.globenewswire.com/news-release/2026/01/14/3218971/0/en/Cosmos-Health-Announces-Initiation-of-Analyst-Coverage-with-4-50-Valuation-by-Zacks-Small-Cap-Research.html
0 · Reply
Luvmepup
Luvmepup Feb. 3 at 10:26 PM
$COSM @Akis1965 Down even in AH! This CEO really has no idea/plan on how to stop this SP from tumbling IMO. He is either purposely dropping this stock price down to accumulate shares or really does not know how to counter Wall Street's games ... either one is terrible for retail.
0 · Reply
Luvmepup
Luvmepup Feb. 3 at 10:18 PM
$COSM @Akis1965 They scattered like the roaches they are once you posted this ... too funny!
0 · Reply
Yatoxksy
Yatoxksy Feb. 3 at 8:06 PM
$COSM @john_acc pleaee remember below . is it worth it for you? i feel that are under pressure from the "boss" to post, but look at others like @marel_corp. they stopped. some deleted all their posts. https://www.stocktwits.com/Yatoxksy/message/642956134
0 · Reply
Luvmepup
Luvmepup Feb. 3 at 6:37 PM
$COSM @Akis1965 You should never trust this crooked CEO over THE Pupstradamus!
0 · Reply
Latest News on COSM
Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue

Jan 20, 2026, 10:45 AM EST - 14 days ago

Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue

Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research

Jan 14, 2026, 11:25 AM EST - 20 days ago

Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research

Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units

Jan 5, 2026, 9:30 AM EST - 4 weeks ago

Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units

Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy

Dec 24, 2025, 9:00 AM EST - 5 weeks ago

Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy

Cosmos Health is Forcing the Market to Reframe the Conversation

Dec 19, 2025, 9:00 AM EST - 6 weeks ago

Cosmos Health is Forcing the Market to Reframe the Conversation

Cosmos Health Launches Strategic Partnership With Prime Ledger to Transform $300M Treasury and Tokenize IP Assets

Dec 3, 2025, 12:20 PM EST - 2 months ago

Cosmos Health Launches Strategic Partnership With Prime Ledger to Transform $300M Treasury and Tokenize IP Assets

Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases

Dec 2, 2025, 12:15 PM EST - 2 months ago

Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases

Cosmos Health Reports Record Q3 2025 Results with All-Time High Revenue, Gross Profit and Gross Margin; Revenue Up 38% to $17.1M, Gross Profit Up 116% to $2.6M, Adjusted EBITDA Up 74%, Cash Position Up to $4.63M from $0.66M

Nov 17, 2025, 9:15 AM EST - 2 months ago

Cosmos Health Reports Record Q3 2025 Results with All-Time High Revenue, Gross Profit and Gross Margin; Revenue Up 38% to $17.1M, Gross Profit Up 116% to $2.6M, Adjusted EBITDA Up 74%, Cash Position Up to $4.63M from $0.66M

Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation Nutraceutical Formulas with Enhanced Phytochemical Efficacy

Oct 31, 2025, 10:45 AM EDT - 3 months ago

Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation Nutraceutical Formulas with Enhanced Phytochemical Efficacy

Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million

Oct 21, 2025, 12:10 PM EDT - 3 months ago

Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million

Cosmos Health Purchases an Additional $300,000 in Ethereum Under Its $300 Million Digital Assets Facility; Total Investment Reaches $1.8 Million

Oct 13, 2025, 2:05 PM EDT - 4 months ago

Cosmos Health Purchases an Additional $300,000 in Ethereum Under Its $300 Million Digital Assets Facility; Total Investment Reaches $1.8 Million

Cosmos Health Purchases an Additional $500,000 in Ethereum Pursuant to its $300 Million Digital Assets Facility

Oct 10, 2025, 8:00 AM EDT - 4 months ago

Cosmos Health Purchases an Additional $500,000 in Ethereum Pursuant to its $300 Million Digital Assets Facility

Cosmos Health Expands Sky Premium Life Into $1Bn+ Kuwait Market; Signs Exclusive Distribution Agreement With Diyar United and Secures Initial Purchase Order of Over 65,000 Units

Oct 3, 2025, 3:56 PM EDT - 4 months ago

Cosmos Health Expands Sky Premium Life Into $1Bn+ Kuwait Market; Signs Exclusive Distribution Agreement With Diyar United and Secures Initial Purchase Order of Over 65,000 Units

Cosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare Powerhouse with $300M Digital Financing Facility, U.S. Manufacturing Expansion, and AI Innovation

Sep 29, 2025, 8:00 AM EDT - 4 months ago

Cosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare Powerhouse with $300M Digital Financing Facility, U.S. Manufacturing Expansion, and AI Innovation

Cosmos Health Expands Order Book with Contract Manufacturing Agreement with Medical Pharmaquality S.A. for 3 Million MYCOFAGYL® Pessaries Annually

Sep 25, 2025, 8:00 AM EDT - 4 months ago

Cosmos Health Expands Order Book with Contract Manufacturing Agreement with Medical Pharmaquality S.A. for 3 Million MYCOFAGYL® Pessaries Annually

Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market with Its Sky Premium Life Brand; Expects 75% Gross Margins and Strong Cash Flow, with NOOR Collagen Alone Projected to Generate Over $12M in Annualized Revenue

Sep 22, 2025, 8:00 AM EDT - 4 months ago

Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market with Its Sky Premium Life Brand; Expects 75% Gross Margins and Strong Cash Flow, with NOOR Collagen Alone Projected to Generate Over $12M in Annualized Revenue

Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units

Sep 11, 2025, 8:00 AM EDT - 5 months ago

Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units

Cosmos Health Reports Q2 2025 Results; Continues Strong Growth with 11.7% Revenue Increase; On Track to Meet Profitability Targets with Gross Profit Up 53% to $3.21M in H1 2025

Aug 18, 2025, 12:45 PM EDT - 6 months ago

Cosmos Health Reports Q2 2025 Results; Continues Strong Growth with 11.7% Revenue Increase; On Track to Meet Profitability Targets with Gross Profit Up 53% to $3.21M in H1 2025

Cosmos Health Makes Initial $1M Ethereum Purchase Under Digital Asset Treasury Strategy

Aug 12, 2025, 9:50 AM EDT - 6 months ago

Cosmos Health Makes Initial $1M Ethereum Purchase Under Digital Asset Treasury Strategy

Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy

Aug 6, 2025, 9:20 AM EDT - 6 months ago

Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy

Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech

Jun 24, 2025, 10:55 AM EDT - 8 months ago

Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech

RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

May 15, 2025, 2:30 PM EDT - 9 months ago

RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

May 15, 2025, 9:30 AM EDT - 9 months ago

Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units

May 7, 2025, 2:30 PM EDT - 9 months ago

Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units

Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq

May 6, 2025, 1:40 PM EDT - 9 months ago

Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

Apr 30, 2025, 12:50 PM EDT - 9 months ago

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

Apr 16, 2025, 12:45 PM EDT - 10 months ago

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L

Apr 9, 2025, 1:40 PM EDT - 10 months ago

Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L

Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order

Apr 8, 2025, 10:45 AM EDT - 10 months ago

Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order

Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates

Feb 26, 2025, 11:30 AM EST - 1 year ago

Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates

Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1

Feb 18, 2025, 8:30 AM EST - 1 year ago

Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1

Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market

Feb 11, 2025, 10:15 AM EST - 1 year ago

Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market

Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market

Feb 10, 2025, 1:30 PM EST - 1 year ago

Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market

Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations

Feb 10, 2025, 9:45 AM EST - 1 year ago

Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations

Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility

Feb 7, 2025, 10:00 AM EST - 1 year ago

Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility

Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar

Feb 6, 2025, 3:50 PM EST - 1 year ago

Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar

Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market

Feb 5, 2025, 11:05 AM EST - 1 year ago

Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market

Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow

Jan 28, 2025, 11:00 AM EST - 1 year ago

Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow

Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion

Jan 27, 2025, 3:50 PM EST - 1 year ago

Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

Jan 23, 2025, 3:35 PM EST - 1 year ago

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

VRAX

Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million

Jan 22, 2025, 8:00 AM EST - 1 year ago

Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

Jan 21, 2025, 3:00 PM EST - 1 year ago

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

Jan 13, 2025, 9:20 AM EST - 1 year ago

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

VRAX

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

Dec 26, 2024, 1:30 PM EST - 1 year ago

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000

Dec 23, 2024, 9:25 AM EST - 1 year ago

Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000

Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets

Nov 18, 2024, 8:00 AM EST - 1 year ago

Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets

Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M

Nov 15, 2024, 10:20 AM EST - 1 year ago

Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M

Cosmos Health Issues Letter to Shareholders

Nov 12, 2024, 12:00 PM EST - 1 year ago

Cosmos Health Issues Letter to Shareholders

Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%

Nov 1, 2024, 12:30 PM EDT - 1 year ago

Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%

Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands

Sep 25, 2024, 9:25 AM EDT - 1 year ago

Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands

Luvmepup
Luvmepup Feb. 4 at 5:56 AM
$COSM Remember this know-nothing? @marel_corp ... They thought they knew more than me and said this stock and CEO was so great! I guess they found out the hard way by not listening to me lol
0 · Reply
BettyGrigg
BettyGrigg Feb. 4 at 5:42 AM
$COSM Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research. https://www.globenewswire.com/news-release/2026/01/14/3218971/0/en/Cosmos-Health-Announces-Initiation-of-Analyst-Coverage-with-4-50-Valuation-by-Zacks-Small-Cap-Research.html $AMD
0 · Reply
LoisMaresi
LoisMaresi Feb. 4 at 5:04 AM
$COSM Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research. https://www.globenewswire.com/news-release/2026/01/14/3218971/0/en/Cosmos-Health-Announces-Initiation-of-Analyst-Coverage-with-4-50-Valuation-by-Zacks-Small-Cap-Research.html $SMCI
1 · Reply
LoisMaresi
LoisMaresi Feb. 4 at 5:02 AM
$COSM Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research. https://www.globenewswire.com/news-release/2026/01/14/3218971/0/en/Cosmos-Health-Announces-Initiation-of-Analyst-Coverage-with-4-50-Valuation-by-Zacks-Small-Cap-Research.html
0 · Reply
SlaveKing
SlaveKing Feb. 4 at 4:59 AM
$COSM So the CEO has been busy buying the stock... Interesting.
0 · Reply
BrandiBenes
BrandiBenes Feb. 4 at 4:57 AM
$COSM Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research. https://www.globenewswire.com/news-release/2026/01/14/3218971/0/en/Cosmos-Health-Announces-Initiation-of-Analyst-Coverage-with-4-50-Valuation-by-Zacks-Small-Cap-Research.html
0 · Reply
Luvmepup
Luvmepup Feb. 3 at 10:26 PM
$COSM @Akis1965 Down even in AH! This CEO really has no idea/plan on how to stop this SP from tumbling IMO. He is either purposely dropping this stock price down to accumulate shares or really does not know how to counter Wall Street's games ... either one is terrible for retail.
0 · Reply
Luvmepup
Luvmepup Feb. 3 at 10:18 PM
$COSM @Akis1965 They scattered like the roaches they are once you posted this ... too funny!
0 · Reply
Yatoxksy
Yatoxksy Feb. 3 at 8:06 PM
$COSM @john_acc pleaee remember below . is it worth it for you? i feel that are under pressure from the "boss" to post, but look at others like @marel_corp. they stopped. some deleted all their posts. https://www.stocktwits.com/Yatoxksy/message/642956134
0 · Reply
Luvmepup
Luvmepup Feb. 3 at 6:37 PM
$COSM @Akis1965 You should never trust this crooked CEO over THE Pupstradamus!
0 · Reply
john_acc
john_acc Feb. 3 at 6:20 PM
$COSM Love record breaking things. Cosmos is firing on all cylinders!! 👌📈
0 · Reply
Luvmepup
Luvmepup Feb. 3 at 4:39 PM
$COSM @Akis1965 Folks, stop giving money to this crooked CEO and his fellow cronies! Wait until they at least start buying with their own cash on the open market! Remember, acquiring shares from the company in lieu of debt owed to this CEO is not the same as if he would be buying like retail has to!
0 · Reply
Luvmepup
Luvmepup Feb. 3 at 4:23 PM
$COSM @Akis1965 Why on earth is anyone buying this garbage when we all know it only goes down the later it gets in the day?
0 · Reply
Luvmepup
Luvmepup Feb. 3 at 4:15 PM
$COSM @Akis1965 Level 2 showing most of the volume is on the selling side!
0 · Reply
Luvmepup
Luvmepup Feb. 3 at 4:11 PM
$COSM @akis1965 You're welcome!
0 · Reply
Luvmepup
Luvmepup Feb. 3 at 4:08 PM
$COSM @Akis1965 NEVER WRONG 😉
0 · Reply
Luvmepup
Luvmepup Feb. 3 at 3:20 PM
$COSM @Akis1965 That didn't take long lol
0 · Reply
Luvmepup
Luvmepup Feb. 3 at 3:15 PM
$COSM @Akis1965 Go ahead and buy this junk!
0 · Reply
Stockships
Stockships Feb. 3 at 2:55 PM
$COSM $COSM... The CEO had been buying shares non stop... I'm keeping COSM on a watchlist to see why. Stockships.com/disclaimer
0 · Reply
Luvmepup
Luvmepup Feb. 3 at 2:50 PM
$COSM @Akis1965 Buy now ... bag later!
0 · Reply
Luvmepup
Luvmepup Feb. 3 at 2:44 PM
$COSM @Akis1965 This CEO's message to retail should be ...
0 · Reply
Luvmepup
Luvmepup Feb. 3 at 2:40 PM
$COSM @Akis1965 RED YET?
0 · Reply